TriangleAndrogen deprivation therapy (ADT) (NCT06150417)
Androgen deprivation therapy (ADT) trial for Prostate Cancer (NCT06150417). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with newly diagnosed hormone-sensitive prostate cancer and bone or distant-node metastases: 1–5 sites on conventional imaging, or up to ten on PSMA PET. PET-only nodal disease has extra criteria.
The idea: test radiation to all metastases alongside hormone treatment and prostate treatment. Random assignment determines whether metastases receive radiation. All receive 12 months of systemic therapy plus prostate radiation or surgery. Researchers measure treatment failure.
This phase 2 study plans 200 patients. Case’s Angela Jia leads it; three US sites recruit in Cleveland, New York and Madison.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.